Additionally, TRAF6 has been shown to directly interact with RIPK1 via Lys48-linked polyubiquitination, reducing p-RIPK1 levels and inhibiting the activation of the RIPK1–RIPK3–MLKL axis in colorectal cancer cells, thereby suppressing necroptosis and promoting tumour progression.84 Here, MLKL is linked to neoplasm.